Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 combined with anlotinib for first-line advanced esophageal cancer
ChiCTR2100045082Phase 4Not yet recruiting
- Sponsor
- Pingmei Shenma Medical Group General Hospital
- Start
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of penpulimab and anlotinib in esophageal cancer, sponsored by Pingmei Shenma Medical Group General Hospital. Primary endpoint: Progression-Free Survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2100045082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045082.